Plethico Pharmaceuticals, a Rs.1,600 crore plus pharma giant from Indore, has suffered heavy setback during the first quarter ended March 2013 on account of FCCBs. Its consolidated net profit declined sharply by 72.1 per cent to Rs.13.24 crore from Rs.47.44 crore in the corresponding period of last year. Its has reported foreign exchange gain Rs.5.32 crore from FCCBs as against Rs.16.73 crore in the similar quarter in the last year. Its total exceptional loss stood at Rs.2.49 crore as against a gain of Rs.37.49 crore. Its EBDITA improved by 104 per cent to Rs.32.10 crore from Rs.15.74 crore.

The company's consolidated net sales improved by 31.6 per cent to Rs.478.96 crore from Rs.363.88 crore in the same period of last year. Its interest cost went up by 22.3 per cent to Rs.15.44 crore from Rs.12.63 crore and employees cost by 11.4 per cent to Rs.32.20 crore from Rs.28.90 crore.

For the full year ended December 2012, Plethico's consolidated net sales amounted to Rs.1,631 crore and its net profit stood at Rs.101 crore with EPS of Rs.33.95.